Professor Rob Howard (UCL Psychiatry), Professor John Hardy and Professor Nick Fox (UCL Institute of Neurology) comment on the failure in late-phase effectiveness trials of solanezumab, a drug which had shown promise for treating Alzheimer's disease in early tests.
Read: The Guardian,
More: Reuters,
BBC News,
Daily Mail
Close
